Overview

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Status:
Completed
Trial end date:
2018-10-08
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)
Phase:
Phase 3
Details
Lead Sponsor:
H. Lundbeck A/S
Treatments:
Olanzapine
Risperidone